Related Experiment Video
Updated: Jun 23, 2026
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Proteasome inhibitors in multiple myeloma
1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Kenneth-Anderson@dfci.harvard.edu
Abstract:
Discovery of the intracellular proteasome system for breakdown and removal of damaged or inappropriate proteins that might trigger apoptosis has led to the development of a whole new class of anticancer agents targeted to inhibit the proteasome and induce apoptosis. In vitro studies in multiple myeloma (MM) provide important insights into the use of proteasome inhibition to target both tumor cells and their microenvironment. Rapid development of the proteasome inhibitor bortezomib from biomolecular observations to clinical trials demonstrates how sophisticated appreciation of potential targets can expand the spectrum of novel agents available to treat difficult cancers, transforming disease management in these patients. In addition, high-throughput advanced protein and gene studies are key to develop preclinical assessments of potentially useful combination therapy and to guide clinical trials to improve efficacy using multiple agents.
Insights
Proteasome inhibitors, like bortezomib, offer a novel anticancer strategy by inducing apoptosis in cancer cells. Advanced proteomic and genomic studies are crucial for developing effective combination therapies for difficult-to-treat cancers.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- The proteasome system degrades damaged proteins, preventing apoptosis.
- Targeting this system offers a novel anticancer therapeutic strategy.
- Multiple myeloma (MM) is a complex cancer benefiting from proteasome inhibition.
Purpose of the Study:
- To explore the role of proteasome inhibition in cancer therapy.
- To highlight bortezomib as a successful proteasome inhibitor.
- To emphasize the importance of advanced molecular studies for combination therapies.
Main Methods:
- In vitro studies on multiple myeloma.
- Development of bortezomib from discovery to clinical trials.
- High-throughput protein and gene expression analysis.
Main Results:
- Proteasome inhibition effectively targets tumor cells and their microenvironment.
- Bortezomib demonstrates successful clinical application in difficult cancers.
- Advanced molecular studies facilitate preclinical assessment of combination therapies.
Conclusions:
- Proteasome inhibitors represent a significant advancement in cancer treatment.
- Targeting the proteasome system induces apoptosis and combats cancer.
- Future cancer therapy relies on sophisticated molecular insights and combination strategies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
01:13The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:18The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...